NIH Institute / Center · AI (NIAID)
National Institute of Allergy and Infectious Diseases
742 funded awards, $473.1M total, FY2023-FY2025.
NIH SBIR/STTR funding decisions are made by Institutes and Centers based on portfolio priorities, NOFO scope, and program officer judgment. Historical funding patterns do not guarantee future funding.
Technology areas funded by NIAID
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
Pattern read
NIAID has been the largest SBIR funder in the dataset at 742 records and $473M. The portfolio is dominated by anti-infective small molecules, vaccines, and infectious-disease research tools. Diagnostic in-vitro work is heavy too (the broader window includes the trailing edge of COVID-era investment). Median award is $694K, near the top of the cross-IC range, reflecting the higher cost of preclinical infectious-disease work. STTR participation is strong (114 R41 records). Concentration is low at 5.9%. The portfolio mix is shifting; pandemic-era investment is winding down, so the three-year averages overstate the size of certain subportfolios going forward.